Paper Details

  1. Home
  2. Paper Details

Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.

Author: AhmadiTahamtan, ArnulfBertrand, Avet-LoiseauHervé, BelhadjKarim, BenboubkerLotfi, BroijlAnnemiek, BénéMarie C, CaillonHélène, CaillotDenis, CorreJill, DejoieThomas, DelforgeMichel, DoyenChantal, Escoffre-BarbeMartine, EveillardJean-Richard, FaconThierry, FontanJean, GaridiRéda, HulinCyrille, JieKon-Siong, KampfenkelTobias, KarlinLionel, KleinSaskia K, KrevvataMaria, KuhnowskiFrédérique, LambertJérôme, LeleuXavier, LevinMark-David, MacroMargaret, MarolleauJean-Pierre, MeulemanNathalie, MohtyMohamad, MoreauPhilippe, OffnerFritz, Orsini-PiocelleFrédérique, PerrotAurore, RousselMurielle, SonneveldPieter, SonntagCécile, StoppaAnne-Marie, TiabMourad, TouzeauCyrille, VanquickelbergheVeronique, VaraSanjay, VekemansMarie-Christiane, VermeulenJessica, WestermanMatthijs, WuillèmeSoraya, ZhangKe, ZweegmanSonja, de BoerCarla, van de DonkNiels W C J

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study compared the effects of daratumumab maintenance versus observation alone in patients with newly diagnosed multiple myeloma who were eligible for autologous stem-cell transplantation (ASCT). Previous research (CASSIOPEIA part 1) showed that daratumumab combined with other treatments led to improved outcomes.
Paper Details　
Original Abstract of the Article :
CASSIOPEIA part 1 showed superior depth of response and significantly improved progression-free survival with daratumumab, bortezomib, thalidomide, and dexamethasone (D-VTd) versus bortezomib, thalidomide, and dexamethasone (VTd) as induction and consolidation in patients with autologous stem-cell t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S1470-2045(21)00428-9

データ提供：米国国立医学図書館（NLM）

Daratumumab Maintenance: A New Frontier in Multiple Myeloma Treatment?

The [multiple myeloma] landscape is constantly evolving, with new treatments emerging to improve outcomes for patients. This study examines the role of [daratumumab] maintenance therapy following [bortezomib], [thalidomide], and [dexamethasone] (VTd) induction and consolidation in patients with [newly diagnosed multiple myeloma]. It's like a new map guiding us to better treatment strategies for this complex disease.

The authors conducted a [phase 3 trial], comparing the effectiveness of [daratumumab] maintenance versus observation alone. They discovered that [daratumumab] maintenance significantly improved [progression-free survival] compared to observation, suggesting that this strategy may be a promising addition to the treatment regimen.

Sustaining Remission: The Promise of Daratumumab

The results of this study are like a cool oasis in the desert of multiple myeloma treatment. By extending the duration of [daratumumab] therapy, the researchers demonstrated a significant improvement in [progression-free survival], suggesting that this strategy may be a key to sustaining remission and improving long-term outcomes for patients.

The Importance of Continued Research

While this study provides encouraging results, it's important to continue researching the long-term effects and optimal use of [daratumumab] maintenance therapy. It's a journey through the desert, requiring ongoing exploration and discovery to ensure the most effective and safe treatments for patients.

Dr.Camel's Conclusion

This study is like a desert bloom, offering hope for patients with [multiple myeloma]. The researchers' findings suggest that [daratumumab] maintenance therapy might be a key to extending remission and improving outcomes. However, like a desert oasis, it's important to remain vigilant and continue researching this promising treatment strategy to ensure its full potential is realized.

Date :
  1. Date Completed 2021-11-01
  2. Date Revised 2021-11-08
Further Info :

Pubmed ID

34529931

DOI: Digital Object Identifier

10.1016/S1470-2045(21)00428-9

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.